Epacadostat
- Generic Name
- Epacadostat
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT03361228
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 89
- Registration Number
- NCT03358472
- Locations
- 🇺🇸
U of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺Royal Brisbane & Women s Hospital, Herston, Queensland, Australia
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03348904
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 11
- Registration Number
- NCT03347123
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03342352
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Conditions
- Advanced Cancer
- Interventions
- Biological: NivolumabBiological: IpilimumabBiological: RelatlimabBiological: CabiralizumabRadiation: Radiation Therapy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03335540
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Local Institution - 0001, Chicago, Illinois, United States
🇺🇸Local Institution - 0003, Pittsburgh, Pennsylvania, United States
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03325465
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
- Conditions
- Advanced Solid TumorsLymphoma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT03322384
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 233
- Registration Number
- NCT03322566
- Locations
- 🇦🇺
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸St. Vincent Healthcare Frontier Cancer Center, Billings, Montana, United States
🇭🇺Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT03322540
- Locations
- 🇺🇸
Anne Arundel Health System Research Institute, Annapolis, Maryland, United States
🇺🇸Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.